Mitsugumin-53: Potential biomarker and therapeutic for myocardial ischemic injury?

Journal of Molecular and Cellular Cardiology

Volumn 81, Issue , 2015, Pages 46-48

  Kohr, Mark J ^a  

^a The Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CREATINE KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITSUGUMIN 53; PHOSPHATIDYLINOSITOL 3 KINASE; PROTECTIVE AGENT; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; TROPONIN I; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; CARRIER PROTEIN;

CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OCCLUSION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INTRACELLULAR SIGNALING; ISCHEMIC PRECONDITIONING; NONHUMAN; REPERFUSION INJURY; ANIMAL; MALE; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOTONIC AGENTS; CARRIER PROTEINS; HUMANS; MALE; MYOCARDIAL REPERFUSION INJURY; RECOMBINANT PROTEINS;

EID: 84922376448     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.01.023     Document Type: Editorial

References (26)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
2. Zweier J.L., Talukder M.A. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006, 70:181-190.
3. Konstantinidis K., Whelan R.S., Kitsis R.N. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 2012, 32:1552-1562.
4. Laflamme M.A., Murry C.E. Heart regeneration. Nature 2011, 473:326-335.
5. Schwartz Longacre L., Kloner R.A., Arai A.E., Baines C.P., Bolli R., Braunwald E., et al. New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation 2011, 124(10):1172-1179.
6. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74(5):1124-1136.
7. Murphy E., Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008, 88(2):581-609.
8. Iliodromitis E.K., Lazou A., Kremastinos D.T. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. Vasc Health Risk Manag 2007, 3(5):629-637.
9. Zhao Z.Q., Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 2002, 55(3):438-455.
10. Tong G., Aponte A.M., Kohr M.J., Steenbergen C., Murphy E., Sun J. Postconditioning leads to an increase in protein S-nitrosylation. Am J Physiol Heart Circ Physiol 2014, 306(6):H825-H832.
11. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., Alexander R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005, 45(11):1775-1780.
12. Piot C., Croisille P., Staat P., Thibault H., Rioufol G., Mewton N., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008, 359(5):473-481.
13. Sun J., Morgan M., Shen R.F., Steenbergen C., Murphy E. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circ Res 2007, 101(11):1155-1163.
14. Hausenloy D.J., Lecour S., Yellon D.M. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011, 14(5):893-907.
15. Liu J., Zhu H., Zheng Y., Xu Z., Li L., Tan T., et al. Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury. J Mol Cell Cardiol 2014, 10.1016/j.yjmcc.2014.12.010.
16. Cai C., Masumiya H., Weisleder N., Matsuda N., Nishi M., Hwang M., et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 2009, 11(1):56-64.
17. Cai C., Masumiya H., Weisleder N., Pan Z., Nishi M., Komazaki S., et al. MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem 2009, 284(5):3314-3322.
18. Steenbergen C., Hill M.L., Jennings R.B. Volume regulation and plasma membrane injury in aerobic, anaerobic, and ischemic myocardium in vitro. Effects of osmotic cell swelling on plasma membrane integrity. Circ Res 1985, 57(6):864-875.
19. Cai C., Weisleder N., Ko J.K., Komazaki S., Sunada Y., Nishi M., et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 2009, 284(23):15894-15902.
20. Kohr M.J., Evangelista A.M., Ferlito M., Steenbergen C., Murphy E. S-nitrosylation of TRIM72 at cysteine 144 is critical for protection against oxidation-induced degradation and cell death. J Mol Cell Cardiol 2014, 69:67-74.
21. Cao C.M., Zhang Y., Weisleder N., Ferrante C., Wang X., Lv F., et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 2010, 121(23):2565-2574.
22. Zhang Y., Lv F., Jin L., Peng W., Song R., Ma J., et al. MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovasc Res 2011, 91(1):108-115.
23. Song R., Peng W., Zhang Y., Lv F., Wu H.K., Guo J., et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 2013, 494(7437):375-379.
24. Weisleder N., Takizawa N., Lin P., Wang X., Cao C., Zhang Y., et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 2012, 4(139):139ra85.
25. Marshall K.D., Edwards M.A., Krenz M., Davis J.W., Baines C.P. Proteomic mapping of proteins released during necrosis and apoptosis from cultured neonatal cardiac myocytes. Am J Physiol Cell Physiol 2014, 306(7):C639-C647.
26. Li X., Xiao Y., Cui Y., Tan T., Narasimhulu C.A., Hao H., et al. Cell membrane damage is involved in the impaired survival of bone marrow stem cells by oxidized low-density lipoprotein. J Cell Mol Med 2014, 18(12):2445-2453.